Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.61 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16111153 | 0.80 | PHGDH (0.44) | HRH3PHGDHP2RX7HTR1ACYP11B1 | |
| SCHEMBL16111150 | 0.78 | PHGDH (0.45) | HRH3PHGDHP2RX7HTR1AROCK2 | |
| SCHEMBL5802241 | 0.77 | KDM4E (0.48) | PHGDHP2RX7 | |
| SCHEMBL12244977 | 0.77 | HRH3 (1.00) | HRH3 | |
| SCHEMBL6924475 | 0.77 | PRKCB (0.46) | PHGDHROCK2ROCK1 | |
| SCHEMBL6924480 | 0.77 | PRKCB (0.46) | PHGDHROCK2ROCK1 | |
| SCHEMBL15488697 | 0.76 | POLB (0.52) | PHGDHP2RX7CYP11B1CYP11B2 | |
| SCHEMBL2420958 | 0.76 | CYP2D6 (0.66) | PHGDHHTR1AROCK2ROCK1 | |
| SCHEMBL14861127 | 0.76 | LATS1 (0.52) | PHGDHP2RX7HTR1A | |
| SCHEMBL4728462 | 0.75 | ROCK2 (0.65) | HRH3HTR1AROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180201603-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3309148-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9944625-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2766346-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20170073330-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-16 | — | — | US | disclosed |
| CN-103974938-B | The tetrahydro isoquinoline compound being substituted as factor XI, plasma thromboplastin antecedent A inhibitor | 百时美施贵宝公司 | 2016-11-09 | — | — | CN | disclosed |
| US-20160318904-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-03 | — | — | US | disclosed |
| US-9447110-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160075715-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-17 | — | — | US | disclosed |
| US-9192607-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150157624-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-11 | — | — | US | disclosed |
| US-9000172-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140296214-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-10-02 | — | — | US | disclosed |
| EP-2766346-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-20 | — | — | EP | disclosed |
| CN-103974938-A | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors | BRISTOL MYERS SQUIBB CO | 2014-08-06 | — | — | CN | disclosed |
| WO-2013056060-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296214-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HRH3 565/4885L3MBTL3 4854/4885L3MBTL1 4824/4885 |
| US-20160318904-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HRH3 565/4885L3MBTL3 4854/4885L3MBTL1 4824/4885 |
| US-20170073330-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HRH3 565/4885L3MBTL3 4854/4885L3MBTL1 4824/4885 |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | TFPI, TFPI2, KLKB1 | HRH3 565/4885L3MBTL3 4854/4885L3MBTL1 4824/4885 |
| US-20160075715-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HRH3 565/4885L3MBTL3 4854/4885L3MBTL1 4824/4885 |
| US-20180201603-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HRH3 565/4885L3MBTL3 4854/4885L3MBTL1 4824/4885 |
| US-20150157624-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HRH3 565/4885L3MBTL3 4854/4885L3MBTL1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.